Owlstone Medical develops non-invasive diagnostics for cancer, inflammatory disease and infectious disease. The company developed a breathalyzer for disease detection. Their Breath Biopsy platform is used to discover novel non-invasive biomarkers in breath which could transition to point-of-care. The ReCIVA Breath Sampler collects breath samples and analyzes volatile organic compounds (VOCs) using the microchip chemical senor technology, FAIMS (High Field Asymmetric waveform Ion Mobility Spectrometry), which detects biomarkers of disease.
Owlstone is developing tests for lung cancer, colorectal cancer and asthma stratification by therapeutic response. The company also offers Breath Biopsy products and services to academic, clinical and pharma partners looking to develop breath based diagnostics for their own applications.
Thermo Fisher, Owlstone Medical collaborate for cancer diagnosis
Owlstone Medical was founded.